TABLE 2.
Body site(s) sampled | % Sensitivity (95% CI)
|
||
---|---|---|---|
MSA-OX (January 2004 to July 2005) | MSA-FOX (August 2005 to January 2006) | MRSA-Select (February 2006 to June 2007) | |
Nares | 67 (61-73) | 64 (53-74) | 70 (65-76) |
Open skin areasa | 74 (59-85) | 75 (51-90) | 71 (56-82) |
Rectum | 59 (53-65) | 55 (44-65) | 67 (61-72) |
Nares and rectumb | 95 (91-97) | 94 (86-98) | 97 (94-98) |
Wounds and device exit sites.
Only patients sampled at both sites were included in the denominator, and patients positive at either site were included in the numerator.